Neoadjuvant Treatment of HER2-Positive Breast Cancer - Pathological Complete Response (Pcr) as a Surrogate of Long Term Outcomes in the Context of Regulatory Guidelines and Reimbursement Recommendations

• Autorzy: Anna Panasiuk , Dariusz Pawlik , Małgorzata Budasz-Świderska , Marcin Kaczor
• Języki publikacji: EN

Abstrakty

EN

Background: The vast heterogeneity of breast cancer (BC) patients, together with relatively long survival in the early stages of the disease, leads to methodological issues in designing clinical trials, particularly in case of therapies targeted for narrow patients subsets. That situation led to the need and search for early, reliable predictors of long-term outcomes.However, in countries adopting HTA methodology to reimbursement decisions non-final ("surrogate") endpoints may not be accepted as a measure of clinical benefit. Methods: We searched PubMed and EMBASE for meta-analyses investigating association of pathologic complete response to BC neoadjuvant therapy with longer-term clinical outcomes. To be eligible analyses had to pool primary studies identified in a systematic manner. The results of the included studies were discussed in the context of current regulatory and reimbursement recommendations. Results: The 4 included meta-analyses varied in methodological approaches, eligibility criteria and number of included patients. Three of them assessed predictive value of pCR in overall non-metastatic BC population and two - in HER2-positive subgroup. The existing differences in conclusions are consistent with the variability in methodological assumptions. Conclusion: Significant heterogeneity of BC population and low number of studies showing substantial treatment effect on pCR could bias the results of "trial-level" analyses. In contrast, studies consistently show significant patient-level association of pCR with clinical outcomes, particularly strong for aggressive tumour subtypes. The existing EMA and FDA guidelines show how to make use of the existing evidence, in spite of its limitations, in a pursuit of satisfying the unmet medical needs. (original abstract)

Słowa kluczowe

EN

Health care protection; Cancer; Medications

PL

Ochrona zdrowia; Choroby nowotworowe; Leki

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2018
• Numer: nr 1
• Strony: 2--12

Twórcy

autor

Anna Panasiuk

• Aestimo s.c., Kraków, Poland

autor

Dariusz Pawlik

• Aestimo s.c., Kraków, Poland

autor

Małgorzata Budasz-Świderska

• Roche Polska Sp. z o.o., Warsaw, Poland

autor

Marcin Kaczor

• Uniwersytet Jegielloński Collegium Medicum, Kraków, Poland

Bibliografia

• European network for Health Technology Assessment (EUnetHTA). Guideline. Endpoints used for Relative Effectiveness Assessment: Clinical Endpoints. Adapted version (2015) based on "Endpoints used for Relative Effectiveness Assessment of pharmaceuticals: Clinical Endpoints" - February 2013. Available from: http://www.eunethta.eu/sites/default/files/WP7-SG3-GL-clin_endpoints_amend2015.pdf [Accessed November 3, 2017].
• Jönsson B. Technology assessment for new oncology drugs. Clin Cancer Res. 2013;19(1):6-11.
• Jönsson B. Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development. Mendelsohn J, Ringborg U, Schilsky R, eds. Molecular Oncology. 2015;9(5):1025-1033.
• International Agency for Research on Cancer. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Cancer fact sheets. Breast Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [Accessed November 6, 2017].
• Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al.; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-92.
• Puliti D, Zappa M. Breast cancer screening: are we seeing the benefit? BMC Medicine 2012;10:106.
• Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010;10(10):955-60.
• Jhan JR, Andrechek ER. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene 2017;36(25):3553-3561.
• European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man. 17 December 2015, EMA/CHMP/703715/2012 Rev. 2. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001124.jsp&mid=WC0b01ac0580034cf3 [Accessed November 3, 2017].
• U.S. Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. October 2014. Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064981.htm [Accessed November 3, 2017].
• Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, et al. Early market access of cancer drugs in the EU. Ann Oncol. 2016;27(1):96-105.
• Pan-Canadian Oncology Drug Review (pCODR). PCODR Expert Review Committee (pERC) Final Recommendation. Final Recommendation for Pertuzumab (Perjeta) for Neoadjuvant Breast Cancer pERC Meeting: April 17, 2015; pERC Reconsideration Meeting: July 2, 2015. Available from: https://www.cadth.ca/perjeta-or-perjeta-herceptin-combo-pack-neoadjuvant-breast-cancer-details [Accessed November 6, 2017].
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG). IQWiG Reports - Commission No. A15-34. Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V. Extract of dossier assessment A15-34, Version 1.0, 27 November 2015.x. Available from: https://www.iqwig.de/en/projects-results/projects/drug-assessment/a15-34-pertuzumab-new-therapeutic-indication-benefit-assessment-according-to-35a-social-code-book-v-dossier-assessment.6943.html [Accessed November 6, 2017].
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG). IQWiG Reports - Commission No. A16-01. Pertuzumab - Addendum to Commission A15-34. Version 1.0, 29 January 2016. Available from: https://www.iqwig.de/en/projects-results/projects/drug-assessment/a16-01-pertuzumab-addendum-to-commission-a15-34.7183.html [Accessed November 6, 2017].
• National Institute for Health and Care Excellence (NICE). Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424). Technology appraisal guidance Published: 21 December 2016. Available from: https://www.nice.org.uk/guidance/ta424 [Accessed November 6, 2017].
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384(9938):164-72.
• Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011;47(14):2084-90.
• Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. JClin Oncol. 2014;32(34):3883-91.
• Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016;2(6):751-60.
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013 (PMG9). Published: 4 April 2013. Available from: https://nice.org.uk/process/pmg9 [Accessed November 9, 2017].
• Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1):153-62.
• Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, et al. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 2015;22(5):486-95.
• Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, et al. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer 2015;22(6):586-95.

Identyfikatory

DOI

10.7365/JHPOR.2018.1.1